Filtered By:
Condition: Hemorrhagic Stroke
Procedure: Kidney Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Characteristics of stroke after liver and kidney transplantation
ConclusionsIn-hospital, perioperative, and hemorrhagic strokes were more common in the LT group than in the KT group. Ischemic stroke subtypes did not differ significantly between the two groups and undetermined etiology was the most common cause of ischemic stroke in both groups. High mortality after stroke was noted in transplantation patients and was associated with in-hospital stroke.
Source: Frontiers in Neurology - March 22, 2023 Category: Neurology Source Type: research

IJERPH, Vol. 16, Pages 326: The Risk of Stroke in Kidney Transplant Recipients with End-Stage Kidney Disease
Ju Wu Chia-Hung Kao Background: The incidence of stroke after kidney transplantation is poorly understood. Our study aimed to determine the incidence and predictors of stroke as well as mortality from stroke in kidney transplant recipients (KTRs). Methods: This retrospective cohort study used the National Health Insurance Research Database in Taiwan to study KTRs (N = 4635), patients with end-stage renal disease (ESRD; N = 69,297), and patients from the general population who were chronic kidney disease (CKD)-free and matched by comorbidities (N = 69,297) for the years 2000 through 2010. The risk of stroke was analyz...
Source: International Journal of Environmental Research and Public Health - January 24, 2019 Category: Environmental Health Authors: Shih-Ting Huang Tung-Min Yu Ya-Wen Chuang Mu-Chi Chung Chen-Yu Wang Pin-Kuei Fu Tai-Yuan Ke Chi-Yuan Li Cheng-Li Lin Ming-Ju Wu Chia-Hung Kao Tags: Article Source Type: research

Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Abstract Chronic kidney disease (CKD), defined as reduced glomerular filtration rate and/or proteinuria, is a serious worldwide health problem. The incidence and prevalence of CKD are increasing with age, and patients with CKD are a population at very high risk for developing stroke. CKD may increase the risk for incident stroke independent of conventional stroke risk factors. A common pathological process including anemia, homocysteine, nitric oxide, oxidative stress, inflammation, and conditions promoting coagulation may be related to the development of stroke in the course of CKD. CKD can also serve as a marker...
Source: Contributions to Nephrology - May 26, 2013 Category: Urology & Nephrology Authors: Kim SJ, Bang OY Tags: Contrib Nephrol Source Type: research

Risk Factors for Stroke in People with End-Stage Kidney Disease: A Cohort Study
Conclusions: These findings could be used to establish reliable estimates of the risk of stroke in people with ESKD and identify those who are most likely to benefit from preventive treatments.Cerebrovasc Dis 2016;42:428-438
Source: Cerebrovascular Diseases - August 9, 2016 Category: Neurology Source Type: research

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis
Conclusion Our meta-analysis revealed a trend for a reduction of the risk of ischemic stroke in hemodialysis patients with AF treated with VKA. The true protective effect may have been underestimated, owing to inclusion of low-risk patients not expected to benefit from anticoagulation and to suboptimal anticoagulation. However, assessment of the overall effect of VKA in hemodialysis patients should also take into account the increased risk of bleeding, in particular of hemorrhagic stroke. Whether new oral anticoagulants provide a better benefit–risk ratio in hemodialysis patients should be the subject of future trials.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

Centrally administered angiotensin‐(1–7) increases the survival of stroke prone spontaneously hypertensive rats
This study is the first to demonstrate the cerebroprotective actions of Ang‐(1–7), including increased survival time, in spSHR. As such, these data reveal a potential therapeutic target for hemorrhagic stroke. This article is protected by copyright. All rights reserved
Source: Experimental Physiology - October 21, 2013 Category: Physiology Authors: Robert W. Regenhardt, Adam P. Mecca, Fiona Desland, Phillip F. Ritucci‐Chinni, Jacob A. Ludin, David Greenstein, Cristina Banuelos, Jennifer L. Bizon, Mary K. Reinhard, Colin Sumners Source Type: research

Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation
Conclusions In our population of HD patients with AF, the mortality is very high. OAT is not associated with increased mortality, while antiplatelet drugs are. OAT seems, on the contrary, associated with a better survival; however, it does not decrease the incidence of ischaemic stroke, whereas it increases the incidence of bleeding. Bleeding risk is lower in subjects in whom the INR is kept within the therapeutic range.
Source: Nephrology Dialysis Transplantation - February 23, 2015 Category: Urology & Nephrology Authors: Genovesi, S., Rossi, E., Gallieni, M., Stella, A., Badiali, F., Conte, F., Pasquali, S., Bertoli, S., Ondei, P., Bonforte, G., Pozzi, C., Rebora, P., Valsecchi, M. G., Santoro, A. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Progeria syndrome in CKD/ESRD
Conclusions: Renal impairment independently associates with greater stroke disability at presentation and worse functional outcomes despite modern stroke care. Nonetheless these patients are also less likely to be thrombolysed for acute ischaemic stroke, which suggests a possible inequity in access to healthcare that requires urgent study.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Power, A., Gill, D., Wietek, N., Lim, J., Tanna, R., Duncan, N., Troyano Suarez, N., Del Nogal Avila, M., Mora Valenciano, I., Olmos Centenero, G., Diez-Marques, M. L., Cortes, M., Lopez Ongil, S., Martin Sanchez, P., Rodriguez Puyol, D., Ruiz Torres, M. Tags: Abstracts Source Type: research

Centrally administered angiotensin‐(1–7) increases the survival of stroke‐prone spontaneously hypertensive rats
This study is the first to demonstrate the cerebroprotective actions of Ang‐(1–7), including increased survival time, in spSHRs. As such, these data reveal a potential therapeutic target for haemorrhagic stroke.
Source: Experimental Physiology - December 6, 2013 Category: Physiology Authors: Robert W. Regenhardt, Adam P. Mecca, Fiona Desland, Phillip F. Ritucci‐Chinni, Jacob A. Ludin, David Greenstein, Cristina Banuelos, Jennifer L. Bizon, Mary K. Reinhard, Colin Sumners Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Use and safety of heparin-free maintenance hemodialysis in the USA
Conclusions Patient markers of increased risk of bleeding and facility region associated with heparin-free HD use. Despite the potential benefits of avoiding heparin use, heparin-free HD was not significantly associated with decreased hazards of death, bleeding or thrombosis, suggesting that it may be no safer than HD with heparin.
Source: Nephrology Dialysis Transplantation - June 18, 2013 Category: Urology & Nephrology Authors: Shen, J. I., Mitani, A. A., Chang, T. I., Winkelmayer, W. C. Tags: Intra- and Extracorporeal Treatment of Kidney Failure Source Type: research

Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
CONCLUSIONS: Statins appear to be generally well-tolerated in kidney transplant recipients. However, statin use might be associated with slightly higher risk of post-transplant diabetes mellitus, cataract, and rhabdomyolysis.PMID:36800538 | DOI:10.2215/CJN.0000000000000124
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 17, 2023 Category: Urology & Nephrology Authors: Sunjae Bae JiYoon B Ahn Kmd Corey Joseph Ryan Whisler Mark A Schnitzler Krista L Lentine Bernard S Kadosh Dorry L Segev Mara A McAdams-DeMarco Source Type: research